> top > docs > PubMed:24993594 > annotations

PubMed:24993594 JSONTXT

Annnotations TAB JSON ListView MergeView

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
24993594-7#0#4#gene1956 840-844 gene1956 denotes EGFR
24993594-0#36#68#gene1956 36-68 gene1956 denotes epidermal growth factor receptor
24993594-0#102#128#diseaseC0007131 102-128 diseaseC0007131 denotes non-small-cell lung cancer
24993594-1#0#17#gene2348 153-170 gene2348 denotes Folate receptor-α
24993594-1#129#143#diseaseC0001418 282-296 diseaseC0001418 denotes adenocarcinoma
24993594-4#24#27#gene8061 421-424 gene8061 denotes FRA
24993594-4#24#27#gene79874 421-424 gene79874 denotes FRA
24993594-4#60#65#diseaseC0007131 457-462 diseaseC0007131 denotes NSCLC
24993594-7#50#57#diseaseC1261473 890-897 diseaseC1261473 denotes sarcoma
36#68#gene1956102#128#diseaseC0007131 24993594-0#36#68#gene1956 24993594-0#102#128#diseaseC0007131 associated_with epidermal growth factor receptor,non-small-cell lung cancer
0#17#gene2348129#143#diseaseC0001418 24993594-1#0#17#gene2348 24993594-1#129#143#diseaseC0001418 associated_with Folate receptor-α,adenocarcinoma
24#27#gene806160#65#diseaseC0007131 24993594-4#24#27#gene8061 24993594-4#60#65#diseaseC0007131 associated_with FRA,NSCLC
24#27#gene7987460#65#diseaseC0007131 24993594-4#24#27#gene79874 24993594-4#60#65#diseaseC0007131 associated_with FRA,NSCLC
0#4#gene195650#57#diseaseC1261473 24993594-7#0#4#gene1956 24993594-7#50#57#diseaseC1261473 associated_with EGFR,sarcoma

DisGeNet-2017-sample

Id Subject Object Predicate Lexical cue
T1758 421-424 gene:8061 denotes FRA
T1759 457-462 disease:C0007131 denotes NSCLC
R1 T1758 T1759 associated_with FRA,NSCLC
R2 T1758 T1759 associated_with FRA,NSCLC

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-138 Sentence denotes Assessment of folate receptor-α and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patients.
TextSentencer_T2 139-152 Sentence denotes INTRODUCTION:
TextSentencer_T3 153-297 Sentence denotes Folate receptor-α regulates cellular uptake of folates and antifolates (eg, pemetrexed) and is frequently expressed in pulmonary adenocarcinoma.
TextSentencer_T4 298-349 Sentence denotes EGFR is an established therapeutic target in NSCLC.
TextSentencer_T5 350-396 Sentence denotes Therapies targeting FRA or EGFR are available.
TextSentencer_T6 397-485 Sentence denotes The association between FRA and EGFR expression in advanced NSCLC has not been explored.
TextSentencer_T7 486-620 Sentence denotes Combining therapeutic FRA antibodies with an EGFR inhibitor might be beneficial, if both of the targets are significantly coexpressed.
TextSentencer_T8 621-642 Sentence denotes PATIENTS AND METHODS:
TextSentencer_T9 643-839 Sentence denotes Specimens from 160 advanced NSCLC patients receiving pemetrexed-based chemotherapy were assessed for membranous FRA and EGFR protein expression using immunohistochemistry and the Hybrid (H)-score.
TextSentencer_T10 840-941 Sentence denotes EGFR (exons 18-21) and Kirsten RNA-associated rat sarcoma 2 virus (exon 2) mutations were determined.
TextSentencer_T11 942-1064 Sentence denotes Results were correlated to patients' clinicopathological data, progression-free survival (PFS), and overall survival (OS).
TextSentencer_T12 1065-1073 Sentence denotes RESULTS:
TextSentencer_T13 1074-1242 Sentence denotes Forty-seven patients (29%) had tumors with strong FRA and EGFR expression, but no statistically significant correlation was seen between protein levels of FRA and EGFR.
TextSentencer_T14 1243-1443 Sentence denotes High membranous FRA expression (H-score ≥ 20) was associated with prolonged PFS (5.5 vs. 3.4 months; hazard ratio [HR], 0.6060; P = .0254) and improved OS (12.1 vs. 6.4 months; HR, 0.5726; P = .0076).
TextSentencer_T15 1444-1455 Sentence denotes CONCLUSION:
TextSentencer_T16 1456-1553 Sentence denotes Survival times are improved in NSCLC patients whose tumors show strong membranous FRA expression.
TextSentencer_T17 1554-1783 Sentence denotes No statistical correlation between membranous FRA and EGFR expression was demonstrated in advanced NSCLC, but 47 patients (29%) had higher expression of both of the receptors and could be suitable for combined targeted therapies.
T1 0-138 Sentence denotes Assessment of folate receptor-α and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patients.
T2 139-152 Sentence denotes INTRODUCTION:
T3 153-297 Sentence denotes Folate receptor-α regulates cellular uptake of folates and antifolates (eg, pemetrexed) and is frequently expressed in pulmonary adenocarcinoma.
T4 298-349 Sentence denotes EGFR is an established therapeutic target in NSCLC.
T5 350-396 Sentence denotes Therapies targeting FRA or EGFR are available.
T6 397-485 Sentence denotes The association between FRA and EGFR expression in advanced NSCLC has not been explored.
T7 486-620 Sentence denotes Combining therapeutic FRA antibodies with an EGFR inhibitor might be beneficial, if both of the targets are significantly coexpressed.
T8 621-642 Sentence denotes PATIENTS AND METHODS:
T9 643-839 Sentence denotes Specimens from 160 advanced NSCLC patients receiving pemetrexed-based chemotherapy were assessed for membranous FRA and EGFR protein expression using immunohistochemistry and the Hybrid (H)-score.
T10 840-941 Sentence denotes EGFR (exons 18-21) and Kirsten RNA-associated rat sarcoma 2 virus (exon 2) mutations were determined.
T11 942-1064 Sentence denotes Results were correlated to patients' clinicopathological data, progression-free survival (PFS), and overall survival (OS).
T12 1065-1073 Sentence denotes RESULTS:
T13 1074-1242 Sentence denotes Forty-seven patients (29%) had tumors with strong FRA and EGFR expression, but no statistically significant correlation was seen between protein levels of FRA and EGFR.
T14 1243-1443 Sentence denotes High membranous FRA expression (H-score ≥ 20) was associated with prolonged PFS (5.5 vs. 3.4 months; hazard ratio [HR], 0.6060; P = .0254) and improved OS (12.1 vs. 6.4 months; HR, 0.5726; P = .0076).
T15 1444-1455 Sentence denotes CONCLUSION:
T16 1456-1553 Sentence denotes Survival times are improved in NSCLC patients whose tumors show strong membranous FRA expression.
T17 1554-1783 Sentence denotes No statistical correlation between membranous FRA and EGFR expression was demonstrated in advanced NSCLC, but 47 patients (29%) had higher expression of both of the receptors and could be suitable for combined targeted therapies.

UBERON-AE

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 117-121 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 117-121 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung